Eli Lilly or Viking Therapeutics: Which Stock Is More Likely to be a Millionaire-Maker?

Core Insights - Eli Lilly and Viking Therapeutics are both engaged in the rapidly growing weight loss drug market, with Eli Lilly's tirzepatide generating significant revenue and Viking's candidates advancing in late-stage clinical trials [1][6]. Industry Overview - The weight loss drug market is projected to reach nearly $100 billion by the end of the decade, indicating strong growth potential for these products [2][6]. Eli Lilly's Position - Eli Lilly's weight loss drugs, particularly Mounjaro and Zepbound, generated over $10 billion in sales in the most recent quarter, showcasing their market leadership alongside Novo Nordisk [3]. - The company is also exploring the introduction of an oral weight loss drug, orforglipron, which is currently under regulatory review and could positively impact stock performance upon approval [4]. Viking Therapeutics' Development - Viking Therapeutics is developing both injectable and oral candidates, currently in phase 3 and phase 2 trials, respectively, with promising results in regulating blood sugar levels and appetite [5]. - There is potential for Viking to capture market share in the obesity drug space, especially if they successfully advance their candidates or secure partnerships or acquisitions with larger companies [6][7].